Ginkgo Bioworks Holdings, Inc. (DNA) is a Biotechnology company in the Healthcare sector, currently trading at $7.72. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is DNA = $8 (+1.6% upside).
Valuation: DNA trades at a trailing Price-to-Earnings (P/E) of -1.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.09.
Financials: revenue is $170M, -27.4%/yr average growth. Net income is $313M (loss), growing at +46.4%/yr. Net profit margin is -183.8% (negative). Gross margin is 81.5% (+24.2 pp trend).
Balance sheet: total debt is $417M against $509M equity (Debt-to-Equity (D/E) ratio 0.82, moderate). Current ratio is 4.92 (strong liquidity). Debt-to-assets is 37.2%. Total assets: $1.1B.
Analyst outlook: 5 / 11 analysts rate DNA as buy (45%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 79/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 58/100 (Partial), Future 34/100 (Fail), Income 10/100 (Fail).
